BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38331434)

  • 1. Outcomes of extracorporeal photopheresis in a diverse cohort of patients with cutaneous T-cell lymphoma: a retrospective study at a tertiary care hospital.
    Weiner DM; Kumar P; Varadhan R; Sweren R; Kim N; Rozati S
    J Dermatolog Treat; 2024 Dec; 35(1):2312250. PubMed ID: 38331434
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma.
    Tran J; Morris L; Vu A; Reddy S; Duvic M
    Dermatol Online J; 2020 Sep; 26(9):. PubMed ID: 33054950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma.
    Duvic M; Chiao N; Talpur R
    J Cutan Med Surg; 2003; 7(4 Suppl):3-7. PubMed ID: 12958700
    [No Abstract]   [Full Text] [Related]  

  • 4. Extracorporeal photopheresis as a treatment for patients with cutaneous T-cell lymphoma: real-world data at a reference cancer centre in Colombia.
    Toquica A; Enciso-Olivera L; Rueda-Lozada X
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e780-e781. PubMed ID: 35596720
    [No Abstract]   [Full Text] [Related]  

  • 5. Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis.
    Gmyrek R; Beer R; Elizeri Y; Oster MW; Silvers DN; Schneiderman P; Grossman ME
    Cutis; 1999 Oct; 64(4):261-4. PubMed ID: 10544882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
    Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
    J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of offline extracorporeal photopheresis in cutaneous T-cell lymphomas: A retrospective study.
    Moreno-Vílchez C; Muniesa C; González-Barca E; García-Muñoz N; Ortega-Sánchez S; Servitje O
    Photodermatol Photoimmunol Photomed; 2023 Nov; 39(6):667-669. PubMed ID: 37465951
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of poikiloderma vasculare atrophicans, a rare variant of cutaneous T-cell lymphoma, responding to extracorporeal photopheresis.
    Kreuter A; Hoffmamm K; Altmeyer P
    J Am Acad Dermatol; 2005 Apr; 52(4):706-8. PubMed ID: 15793532
    [No Abstract]   [Full Text] [Related]  

  • 9. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma.
    Dippel E; Schrag H; Goerdt S; Orfanos CE
    Lancet; 1997 Jul; 350(9070):32-3. PubMed ID: 9217723
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous T-cell lymphoma and cutaneous graft-versus-host disease. Two indications for photopheresis in dermatology.
    Girardi M; Heald PW
    Dermatol Clin; 2000 Jul; 18(3):417-23, viii. PubMed ID: 10943537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
    Br J Dermatol; 2023 Oct; 189(5):e97. PubMed ID: 37879744
    [No Abstract]   [Full Text] [Related]  

  • 12. [Photopheresis for cutaneous T-cell lymphomas].
    Laroche L
    Ann Dermatol Venereol; 2005 Sep; 132 Spec No 2():5S37-8. PubMed ID: 16385898
    [No Abstract]   [Full Text] [Related]  

  • 13. [Extracorporeal photopheresis].
    Prinz B; Plewig G
    Hautarzt; 1994 Nov; 45(11):746-50. PubMed ID: 7822197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T-cell lymphoma.
    Aires D; Abhyankar S
    Hematol Oncol; 2023 Dec; 41(5):809-816. PubMed ID: 37974524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.
    Suchin KR; Cucchiara AJ; Gottleib SL; Wolfe JT; DeNardo BJ; Macey WH; Bromley PG; Vittorio CC; Rook AH
    Arch Dermatol; 2002 Aug; 138(8):1054-60. PubMed ID: 12164743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis.
    Demierre MF; Ferzli P; Miller D
    Arch Dermatol; 2007 May; 143(5):659-61. PubMed ID: 17515522
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
    Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
    Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
    Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
    J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
    [No Abstract]   [Full Text] [Related]  

  • 19. Aggressive squamous cell carcinomas in patients treated with extracorporeal photopheresis for cutaneous T-cell lymphoma.
    Nehal KS; Green KB; Lim HW
    Arch Dermatol; 1995 Oct; 131(10):1211-2. PubMed ID: 7574848
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
    Bisaccia E; Vonderheid EC; Geskin L
    Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.